I’ve received a ton of reader questions about Eli Lilly’s GLP-1 weight loss pill Foundayo, which was recently granted FDA approval. In Part 1 we’ll talk about the study itself, in Part 2 we’ll break down the discussion, limitations and talk about the special treatment the government gave this drug.<br><br>Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

Reader Question - What is Foundayo? Part 1 - Study Basics

Weight and Healthcare 

Reader Question What is Foundayo Part 1, Study Basics? This is the Weight and Healthcare newsletter. If you like what you're hearing, please consider subscribing and or sharing at weightandhealthcare.com. I've received a ton of reader questions about Eli Lilly's GLP-1 weight loss pill, Foundayo, which was recently granted FDA approval. In Part 1, we'll talk about the study itself.

In Part 2, we'll break down the discussion section, limitations section, and talk about the special treatment the government gave this drug. So here's your too-long-didn't-listen summary. A group of authors, all of whom are either taking money from Eli Lilly or employees and stockholders of Eli Lilly, conducted a trial of a weight loss drug manufactured by Eli Lilly, which Eli Lilly not only funded, but also designed and oversaw,

including with its employees guiding everything from medical oversight to statistical analysis to writing the first draft. The study tested Orforglipron, brand name Foundayo, a daily GLP-1 weight loss pill. The trial tested doses of 6 mg, 12 mg, and 36 mg after a titration up from 1 mg against a placebo group. All groups were given the same advice around healthy eating and movement.

At the end of the 72-week trial, 34.7% of the pooled drug group failed to lose 5% of their body weight, 57.4% of the pooled drug group failed to lose 10%, 76.2% failed to lose 15%, and 88.7% failed to lose 20%. While all groups, including placebo, experienced health benefits, the drug groups experienced relatively small but statistically significantly greater benefits.

That said, the authors didn't actually track behaviors and so it is not clear if the drug or if behaviors created the difference in actual health markers rather than weight loss. Deeper dive. We'll start, as we always do, with the authors.

Reader Question - What is Foundayo? Part 1 - Study Basics

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Reader Question - What is Foundayo? Part 1 - Study Basics

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.